BioNxt Solutions (BNXT) AI Stock Analysis

• Market Cap: C$52.99M
• Dividend Yield: N/A
• Average Volume (3M): 80.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: -62.34%
• EPS Growth: 9.80%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 121,810,260
• 10 Day Avg. Volume: 59,081
• 30 Day Avg. Volume: 80,860
• PEG Ratio: 0.20
• Price to Book (P/B): -5.39
• Price to Sales (P/S): 1568.84
• P/FCF Ratio: -13.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.42 ▼(-34.69% Downside)

The score is driven mainly by very weak financial performance (losses, negative equity, rising debt, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess given negative earnings and no dividend support, providing limited offset.

Positive Factors

Diverse revenue streams

Multiple revenue channels — direct product sales, licensing, milestone payments and collaborative research — create durable cash inflows and lower single-product risk. Licensing and milestones can provide recurring or milestone-linked revenue even if product sales grow slowly.

Specialized product focus

A focus on bioanalytical tools and advanced diagnostic assays targets high-value niches in drug development and personalized medicine. This specialization supports sustained demand from pharma and research institutions and creates higher technical barriers to entry.

Partnerships enhance market access

Collaborations and strategic partnerships with established industry players provide durable commercialization, distribution and co-development advantages. These relationships can accelerate adoption, reduce go-to-market costs and create licensing or royalty upside over time.

Negative Factors

Declining revenue trend

Sustained and material revenue declines undermine scale economics and the company’s ability to fund R&D and commercialization internally. Without stabilizing or growing sales, achieving operating breakeven is unlikely and partner confidence may erode over the medium term.

Negative equity and rising debt

Negative equity combined with rising debt signals solvency stress and elevated refinancing or dilution risk. This restricts financial flexibility for capex, R&D or partnerships and increases vulnerability to adverse funding conditions over the coming months.

Persistent cash burn

Ongoing negative operating and free cash flow forces dependence on external financing, raising dilution or debt-servicing needs. Persistent cash burn constrains investment in product development and commercialization, making long-term growth plans contingent on funding access.

BioNxt Solutions Business Overview & Revenue Model

Company Description

BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BioNxt Solutions generates revenue through a multi-faceted approach that includes the sale of proprietary diagnostic assays and biopharmaceutical products. The company earns income from direct product sales to healthcare providers and research institutions, as well as through licensing agreements with pharmaceutical companies for its technologies. Additionally, BNXT may engage in collaborative research initiatives with industry partners, which can lead to milestone payments and royalties on future product sales. Strategic partnerships with established players in the biotechnology and pharmaceutical sectors further enhance its revenue potential by expanding market access and increasing product visibility.

BioNxt Solutions Financial Statement Overview

Summary

BioNxt Solutions is facing significant financial challenges across all verticals. The income statement shows consistent losses, the balance sheet reveals high leverage and negative equity, and the cash flow statement indicates poor cash generation. The company needs strategic restructuring and improved operational efficiency to stabilize its financial position.

Income Statement

BioNxt Solutions has been experiencing declining revenues over the past few years, with a significant drop from 2023 to 2024. Despite a gross profit margin of 100% in 2024, the company continues to face substantial net losses, indicating poor control over operating expenses and high negative EBIT and EBITDA margins. The negative net profit margin suggests persistent profitability challenges.

Balance Sheet

The company has a negative stockholders' equity, indicating that its liabilities exceed its assets, which is a major financial risk. The debt-to-equity ratio is not meaningful due to negative equity, but the high level of debt relative to assets suggests leverage concerns. Return on equity is negative due to net losses, and the equity ratio is negative, signifying financial instability.

Cash Flow

BioNxt Solutions' cash flow situation is troubling, with consistently negative free cash flow and operating cash flow. The free cash flow growth rate is negative, indicating worsening cash flow generation. The operating and free cash flow to net income ratios are not favorable, reflecting inefficiencies in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.82K	26.98K	372.25K	297.44K	286.50K	345.65K
Gross Profit	-12.51K	26.98K	372.25K	195.62K	199.48K	345.65K
EBITDA	-4.95M	-4.32M	-6.48M	-11.51M	-19.19M	-16.05M
Net Income	-6.18M	-5.31M	-7.72M	-12.38M	-20.64M	-16.89M
Balance Sheet
Total Assets	1.23M	569.36K	1.27M	1.61M	9.73M	8.28M
Cash, Cash Equivalents and Short-Term Investments	468.76K	32.35K	363.65K	136.20K	1.35M	2.58M
Total Debt	8.33M	4.28M	4.89M	4.37M	5.46M	3.31M
Total Liabilities	9.54M	8.43M	6.55M	5.74M	8.06M	4.28M
Stockholders Equity	-8.31M	-7.86M	-5.28M	-4.13M	1.67M	4.01M
Cash Flow
Free Cash Flow	-5.18M	-3.03M	-5.37M	-6.23M	-12.61M	-10.36M
Operating Cash Flow	-5.18M	-3.03M	-5.17M	-6.23M	-12.16M	-10.20M
Investing Cash Flow	83.63K	56.21K	100.84K	-3.86K	-5.31M	-156.47K
Financing Cash Flow	5.49M	2.64M	5.29M	5.02M	16.23M	12.65M

BioNxt Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.68, and below the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 24.44 is Positive, neither overbought nor oversold. The STOCH value of 34.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.

BioNxt Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	58 Neutral	C$95.64M	133.80	0.87%	―	2.14%	-83.06%
MPH	54 Neutral	C$12.52M	-3.59	-18.39%	―	24.30%	-68.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	44 Neutral	C$5.29M	-0.95	-148.48%	―	-46.59%	8.26%
BNXT	42 Neutral	C$52.99M	-9.55	―	―	-62.34%	9.80%
INNO	40 Neutral	C$38.51M	-8.10	-71.80%	―	-3.94%	-17.62%
RVV	39 Underperform	C$6.28M	-0.58	-664.21%	―	―	-80.42%

BioNxt Solutions Corporate Events

BioNxt Signs Agreement for Sublingual Chemotherapy and Immunosuppressant Innovation

BioNxt Solutions Inc. has entered into a letter agreement to co-develop a novel sublingual drug formulation for chemotherapy and immunosuppressant treatments, securing exclusive intellectual property rights in collaboration with a European-based chemotherapy company. The partnership involves prototype development and regulatory progression, with expected provisional patent filings by year-end. This initiative aligns with BioNxt’s broader portfolio goals and takes advantage of a growing immunosuppressant market projected to reach USD 61.05 billion by 2025.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures Eurasian Patent for Sublingual Cladribine Platform

BioNxt Solutions Inc. has secured a final patent grant from the Eurasian Patent Organization for its sublingual thin-film cladribine platform, marking a significant milestone in its strategic global intellectual property expansion. The patent, valid until June 2043, protects the formulation across eight Eurasian countries with a population exceeding 200 million, highlighting BioNxt’s push for commercialization and partnership opportunities. BioNxt is advancing patent efforts in major pharmaceutical markets such as the EU, US, Canada, and Japan, aiming to bolster its position within the healthcare industry and enhance treatment outcomes globally.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Unveils Innovative Oral Film to Transform MS Treatment

BioNxt Solutions is advancing its proprietary ‘Melt in Your Mouth’ cladribine film for multiple sclerosis (MS) patients who struggle with swallowing tablets, a common but under-recognized issue known as dysphagia. By offering this innovative sublingual drug-delivery format, BioNxt aims to improve treatment adherence, safety, and accessibility. Positioned within growing global markets for cladribine and oral transmucosal technologies, this development enhances the company’s competitive standing and addresses a significant unmet need in MS treatment.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures Eurasian Patent Readiness for Sublingual Drug Delivery

BioNxt Solutions Inc. has received a ‘Readiness to Grant’ notification from the Eurasian Patent Organization for its patent application on sublingual delivery of anticancer drugs, specifically for treating autoimmune neurodegenerative diseases. This development is a significant step in BioNxt’s commercialization strategy, as it prepares for a large-mass animal bioequivalence study and further international patent nationalization, enhancing its intellectual property portfolio and market positioning in key global regions.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Secures European Patent for Innovative MS Treatment

BioNxt Solutions Inc. has received an ‘Intention to Grant’ notification from the European Patent Office for its sublingual thin-film formulation of cladribine, aimed at treating multiple sclerosis and related diseases. This patent, along with others in Eurasia, strengthens BioNxt’s position in the global market for oral drug delivery, aligning with the trend towards patient-friendly therapies in the European MS market, which is projected to grow significantly. The company’s innovative formulation offers a convenient, non-invasive alternative to traditional treatments, potentially improving patient adherence and quality of life.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Completes Debt Settlement to Strengthen Financial Position

BioNxt Solutions Inc. has successfully completed a debt settlement with an arm’s length creditor, resolving $225,010 in debt through the issuance of 112,505 common shares and a cash payment of $112,505. This strategic move helps BioNxt manage its financial obligations while maintaining focus on its core operations and market expansion efforts.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Advances Cladribine Formulation with New Study

BioNxt Solutions has initiated a large-mass animal bioequivalence study for its lead product, BNT23001, a sublingual Cladribine formulation for multiple sclerosis treatment. This study aims to optimize dosing parameters for an upcoming human bioequivalence study planned for early 2026, potentially enhancing the product’s market positioning by improving drug absorption and patient compliance. The company is also advancing patent nationalization in key global markets, with favorable communications from European and Eurasian patent offices, indicating strong intellectual property protection.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.